- Takeda’s investigational TYK2 inhibitor zasocitinib (TAK-279) achieved statistical superiority over deucravacitinib across all primary and key secondary endpoints in the Phase 3 LATITUDE Atlas study in adults with moderate-to-severe plaque psoriasis.
- More than 35% of patients treated with zasocitinib achieved complete skin clearance (PASI 100) at Week 16, exceeding the response rate seen with deucravacitinib by more than 2.5-fold.
- Zasocitinib also demonstrated superior PASI 90 and sPGA 0 responses at Week 16, while maintaining a safety and tolerability profile consistent with previous studies, with no new safety signals reported.
- The global study enrolled 606 patients across eight countries, including 73 participants from Canada, and Takeda plans to submit regulatory applications for psoriasis starting this fiscal year.
Takeaways:
Zasocitinib’s Phase 3 win over deucravacitinib suggests it could become a best-in-class oral TYK2 option for moderate-to-severe plaque psoriasis if regulators approve it. The head‑to‑head, 606‑patient LATITUDE Atlas trial across eight countries (including Canada) gives Takeda strong comparative data, and the company plans to start regulatory submissions for psoriasis this fiscal year, positioning zasocitinib to compete directly with Sotyktu and biologics as an efficacy‑rich, once‑daily oral alternative
Source: CA Newswire
